Roland Turck

Managing Partner

2015

My Team and I help small and large companies to develop and commercialize their Specialty Medicine assets: bridging the gap between Science and Commerce... We are focused on Specialty Medicine : Oncology , Rare Diseases , CNS , and Ophthalmology. Radiopharmaceuticals: We have deep expertise with diagnostic and therapeutic radiopharmaceuticals. We assist investors, boards and executive teams to assess opportunities and develop strategies. Preparing for commercial success: Commercial Strategy , Strategic Marketing - Clinical Development Strategies - Market Access - Product Launches - Target Product Profiles - Positioning Expanding business: Franchise Development - P&L improvement - Organizational Development - International Expansion - Create a US presence for EU and Asian companies Getting the fundamentals right: Funding and Investor Strategies - Corporate Strategy Examples of recent work include: • Technology assessment for US and EU investors • Senior adviser to the Board of Actinium Pharmaceuticals (NYSE: ATNM) • Revised development plan for a private Oncology company to optimally prepare for successful market access and commercialization • Designed development strategy for an early stage Oncology company to maximize asset value • Identified opportunities to improve bottom-line and increase value in the mid-term for a mid-cap public Pharmaceutical company • Opportunity assessment for Private Equity fund • Designed strategy for a mid-cap Pharmaceutical company. • Helped biotech to focus their activities and to build a compelling story in order to attract funding • Developed strategy and helped securing series A and B funding for a medical device start-up. • Developed commercialization strategy for an in-vitro diagnostic start-up company. • Invest in start-ups outside of Biotech and mentor entrepreneurs as angel investor, Co-Chair of EF Angels. Visit: www.TurckBio.com

Expert Witness

2018

Expert Witness experience: - Expert reports (affirmative reports, rebuttals) - Bench trials, jury trials, arbitration - Depositions - Court testimony

General Partner

2020

Early stage Venture Capital (pre-Seed, Seed)

Venture Capital Investor

2013

- Angel investor - Co-Chair EF Angels (since 2014) - Mentor at ERA (since 2015) - Mentor at NYU Stern Endless Frontier Labs (since 2019)

Member of the Editorial Board

2016 - 2018

President & COO

2013 - 2015

Formula is an early clinical stage Biotechnology company that licensed a CAR-CIK technology well differentiated from current approaches. Formula has raised series B funds to take a CD-19 directed asset into clinical phase 2 development in various indications creating significant value inflection points in the next 2.5 years. - Designed business and R&D development plan as well as R&D operations plan to secure major series B financing - Developed and execute fund raising and partnering strategy - Raised capital and profiled Formula in roadshows for strategic and financial investors jointly with the CEO The company was acquired. http://www.formulapharma.com/

President Global Business Unit Specialty Medicine & Diagnostic Imaging

2010 - 2012

Transformed Specialty Medicine into the top growth driver for Bayer Healthcare with a projected 10 year double-digit CAGR and accelerated profit growth, improved short- and long-term P&L, prepared successful global launches, increased the portfolio value by more than 40%, improved cross-functional collaboration and built a strong, cohesive team. Member of the global Pharma Executive Committee. -Managed US$ 4 B Global Business. Responsible for commercialization, brand strategy and portfolio development throughout the entire life cycle for Oncology, Orphan Drug / Hematology, Neurology, Ophthalmology and Diagnostic Imaging -Maximized portfolio growth and profitability by refocusing US$1B Oncology and US$1.2B Neurology businesses, turned US$1.3B Hematology business around gaining 2% points market share through growth in the US and Emerging Markets -Prepared four major global launches: Ophthalmology: Eylea (wAMD), Oncology: Stivarga (CRC, GIST), Xofigo (Prostate Ca), Nexavar (Thyroid) -Fundamentally re-structured US$1.2B Diagnostic Imaging business and divested non-profitable businesses -Transformed Oncology from single asset business into a rapidly growing, sustainable franchise. Built strategy to market leadership in Hematology. Established Bayer as significant player in the Ophthalmology Retina space -Built strong pipelines in Oncology with internal and external assets. Expanded life cycle management programs. Improved competitiveness in Neurology with an innovative device deal -Created an award winning, externally and internally well recognized Leadership Team -Achieved high level of competitiveness in Oncology by strongly improving execution in R&D and commercialization, and by upgrading talent pool. Shaped clinical development from a commercial perspective from pre-clinical stages on. Achieved alignment with Regions and Functions through transparency and close collaboration

Bayer Schering Pharma President Latin America

2006 - 2010

Full P&L responsibility. Formed a highly competitive and successful organization. Grew business faster than market (13% CAGR), increased profit by 21% CAGR, and significantly reduced working capital. - Managed US$1.5B Region (4th largest pharmaceutical company) with full P&L responsibility for the entire portfolio (Women's Health, Neurology, Oncology, Orphan Drugs, Cardiology, General Medicine), 44 legal entities, approx. 3500 employees. Matrix responsibility for clinical development, medical affairs, finance, production, and all support functions. Reporting to the Executive Committee. - Led integration of Bayer and Schering, built a strong leadership team, created a customer and market oriented, performance driven, entrepreneurial and participative organization. Built lean regional structure to leverage synergies across the Region, establish best practices and assure strategy implementation - Developed and successfully implemented strategy to grow above market while increasing profitability, expand customer franchises and become an employer of choice - Expanded portfolio leveraging internal and external asset opportunities, secured access to selected branded generics portfolio, turned around Central American Generics business - Drove regional re-engineering project further improving execution excellence, flexibility and customer focus while over-exceeding financial targets by 90% - Strengthened talent management focusing on attracting, developing and retaining local talent. Increased number of regional country managers reducing expatriates - Improved compliance through processes, communication and programs highlighting the opportunity to create sustainable competitive advantages - Established reputation of Latin America as a reliable profit contributor, driver of innovative Emerging Market business models and consistently strategy driven organization.

President & CEO

2004 - 2006

Full P&L responsibility - Sales in 2006: approx. 120 million US$, approx. 300 employees, grew sales faster than market and more than doubled profit. - Set a successful company up for mature growth phase while maintaining entrepreneurial spirit of a small organization - Adjusted recently concluded strategy to reflect new priorities without disenfranchising the organization - Re-organized organization establishing P&L accountable, empowered Business Units, solid cross BU processes, strengthened leadership team and aligned incentives with strategy. Restructured Finance unit and cleaned balance sheet. - Developed well established self-confident, entrepreneurial culture towards a stronger focus on profit, effectiveness and return on investment - Launched 5 products - Oncology (Zevalin, Campath), Orphan Drug (Ventavis), Women’s Health (Yasmin), Diagnostic Imaging (Gadovist), concluded local business development deals to strengthen franchises. - Managed media crisis and its fallout - Led Berlex through Bayer takeover, maintaining motivation and addressing anxiety while still achieving best sales and profit ever in the last year

Director

2002 - 2004

- Led major re-organization project for the US organization leading to improved profitability and reduced complexity - Drove various projects (built business analytics, Primary Care Physician cover rightsizing, one face to the customer CRM system, Diagnostic Imaging / PET market assessment, etc.) to improve marketing effectiveness and customer experience

General Manager

2000 - 2002

- Gained general management experience - Turned around a dysfunctional organization, established leadership team, corporate values, processes etc. - Rebuilt business after losing top two products to generics, achieved dominant market leadership with Betaseron (Neurology) and Fludara (Oncology), launched Orphan Drug (Ilomedin)